Lead Evaluation for Defibrillation and Reliability Post Approval Study

Inclusion Criteria: * Patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements * Patient has, or is intended to receive or be treated with an OmniaSecure™ defibrillation lead. * Patient is consented prior to or within 30 days of the therapy received or consented as continuation from the LEADR Pivotal study Exclusion Criteria: * Patient who is, or is expected to be, inaccessible for follow-up * Patient is excluded by local local law * Patient is currently enrolled or plans to enroll in any concurrent drug and/or device study that may confound the Product Surveillence Registyr (PSR) results